Target type: biologicalprocess
Any process that activates or increases the frequency, rate, or extent of fractalkine production. [GOC:mah]
Positive regulation of fractalkine production is a complex biological process that involves a cascade of molecular events culminating in the increased synthesis and release of the chemokine fractalkine. Fractalkine, also known as CX3CL1, is a transmembrane protein expressed on the surface of various cell types, including endothelial cells, neurons, and microglia. It plays a crucial role in mediating cell-cell interactions, inflammation, and immune responses.
The production of fractalkine is tightly regulated, and its expression is influenced by various factors, including inflammatory stimuli, cytokines, and growth factors. When cells are exposed to these signals, they activate intracellular signaling pathways that lead to the upregulation of fractalkine expression.
One of the key pathways involved in positive regulation of fractalkine production is the NF-κB pathway. Upon activation by inflammatory stimuli such as TNF-α, IL-1β, or LPS, the NF-κB transcription factor translocates to the nucleus and binds to the promoter region of the fractalkine gene, enhancing its transcription and translation.
Other signaling pathways, such as the MAPK pathway, also contribute to the regulation of fractalkine production. Activation of the MAPK pathway, which is triggered by various stimuli including growth factors and stress signals, can lead to the phosphorylation and activation of transcription factors such as AP-1, which can bind to the fractalkine promoter and stimulate its expression.
In addition to signaling pathways, post-transcriptional mechanisms also play a role in regulating fractalkine production. For instance, microRNAs (miRNAs) can bind to the 3' untranslated region (UTR) of the fractalkine mRNA, leading to its degradation or translational repression. Conversely, certain miRNAs can promote the expression of fractalkine by targeting the 3' UTR of its repressors.
The increased production of fractalkine has various biological consequences. It contributes to the recruitment and activation of immune cells, such as monocytes and T cells, to sites of inflammation, promoting the resolution of infection or injury. Fractalkine also plays a role in neuronal function and synaptic plasticity, influencing neuronal survival and communication.
The regulation of fractalkine production is essential for maintaining tissue homeostasis and immune responses. Dysregulation of this process can contribute to various pathological conditions, including inflammatory diseases, neurodegenerative disorders, and cancer. Therefore, understanding the molecular mechanisms underlying positive regulation of fractalkine production is crucial for developing novel therapeutic strategies targeting these diseases.'
"
Protein | Definition | Taxonomy |
---|---|---|
Tumor necrosis factor | A tumor necrosis factor that is encoded in the genome of human. [PRO:DNx] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
mesalamine | mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position. Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed) | amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols | non-steroidal anti-inflammatory drug |
way 151693 | |||
pentoxifylline | oxopurine | ||
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone | 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone: Inhibitor of phosphodiesterases. | methoxybenzenes | |
rolipram | pyrrolidin-2-ones | antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor | |
sulfasalazine | sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position. Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) | ||
bergenin | bergenin: RN refers to (2R-(2alpha,3beta,4alpha,4aalpha,10bbeta))-isomer; structure | trihydroxybenzoic acid | metabolite |
marimastat | marimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide. marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary | hydroxamic acid; secondary carboxamide | antineoplastic agent; matrix metalloproteinase inhibitor |
birb 796 | aromatic ether; morpholines; naphthalenes; pyrazoles; ureas | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator | |
ganoderic acid a | triterpenoid | ||
ganoderiol f | ganoderiol F: a ganoderma triterpene from Ganoderma amboinense; structure in first source | triterpenoid | |
1-(phenylmethyl)benzimidazole | benzimidazoles | ||
luteolin-7-glucoside | luteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage. luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum | beta-D-glucoside; glycosyloxyflavone; monosaccharide derivative; trihydroxyflavone | antioxidant; plant metabolite |
apigetrin | apigenin 7-O-beta-D-glucoside : A glycosyloxyflavone that is apigenin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage. apigetrin: structure given in first source | beta-D-glucoside; dihydroxyflavone; glycosyloxyflavone; monosaccharide derivative | antibacterial agent; metabolite; non-steroidal anti-inflammatory drug |
calycosin-7-o-beta-d-glucopyranoside | calycosin-7-O-beta-D-glucoside : A glycosyloxyisoflavone that is calycosin substituted by a beta-D-glucopyranosyl residue at position at 7 via a glycosidic linkage. calycosin-7-O-beta-D-glucoside: from Radix Astragali | 4'-methoxyisoflavones; 7-hydroxyisoflavones 7-O-beta-D-glucoside; hydroxyisoflavone; monosaccharide derivative | |
spd-304 | SPD-304: structure in first source | ||
ganoderic acid f | ganoderic acid F: isolated from Ganoderma lucidum; structure in first source | triterpenoid | |
ganoderic acid c2 | ganoderic acid C2: from the fruiting body of Ganoderma; structure in first source | triterpenoid |